Giant Cell Arteritis Drugs Market Trends, Competitive Landscape and Forecast, 2026–2035

Giant Cell Arteritis Drugs Market Size & Forecast 2035

The global giant cell arteritis drugs market reached USD 1.11 billion in 2025 and is expected to reach USD 2.62 billion by 2035, growing at a CAGR of 9% during 2026–2035. Revenue includes corticosteroids, conventional immunosuppressive medicines, biologic therapies, oral targeted agents and supportive drugs prescribed for giant cell arteritis (GCA), also known as temporal arteritis.

GCA is an immune-mediated vasculitis that mainly affects adults aged 50 years and older. Inflammation of the cranial and large arteries can cause headache, jaw claudication, visual disturbance, stroke and aortic complications. Immediate glucocorticoid treatment remains essential when the disease is suspected because irreversible sight loss can occur. The commercial market is nevertheless shifting from prolonged steroid dependence toward steroid-sparing regimens that sustain remission and reduce cumulative glucocorticoid exposure.

Tocilizumab established interleukin-6 receptor inhibition as the first approved biologic approach for GCA. Upadacitinib subsequently introduced an oral targeted option and widened the competitive field beyond injectable biologics. This transition is raising the treated value per patient, increasing the role of rheumatology-led long-term management and creating room for branded innovation, biosimilars and evidence-based treatment sequencing.

Giant Cell Arteritis Drugs Market Scope

Key Highlights

• The market is forecast to add USD 1.51 billion in annual revenue between 2025 and 2035.
• Biologics led drug-type revenue with a 43.5% share in 2025, equal to USD 482.3 million.
• Subcutaneous products generated 46% of 2025 revenue, supported by established self-injection regimens for IL-6 inhibition.
• Hospital pharmacies accounted for 49% of sales because diagnosis, treatment initiation and reimbursement authorization are concentrated in specialist settings.
• North America held 42% of global revenue in 2025; the United States alone represented 36%.
• Oral targeted therapy is changing the route mix by offering a non-injectable steroid-sparing option for eligible adults.
• Patent transitions and tocilizumab biosimilars are broadening access while increasing price competition within the biologic segment.

Market Dynamics

Growth Drivers

Ageing populations expand the diagnosable patient pool. GCA occurs almost exclusively after age 50 and incidence rises sharply in older age groups. Population ageing in North America, Europe and parts of Asia supports sustained growth in newly diagnosed and relapsing cases. Greater awareness among primary-care physicians, ophthalmologists and emergency departments is also shortening referral time for patients with new headache, elevated inflammatory markers or visual symptoms.

Steroid-sparing treatment has become a clinical priority. High-dose glucocorticoids control acute vascular inflammation but prolonged use can lead to infection, osteoporosis, diabetes, cataracts and cardiovascular complications. Treatments that reduce relapse and cumulative steroid exposure therefore command clinical and economic value. Longer-duration data for targeted therapies strengthen physician confidence in maintenance treatment and support payer discussions around avoided toxicity.

Treatment choice is expanding. The market has progressed from a corticosteroid-dominated model to one that includes an IL-6 receptor inhibitor, biosimilar versions of tocilizumab and an oral JAK inhibitor. Multiple mechanisms and routes permit more individualized treatment, especially for relapsing disease, glucocorticoid toxicity risk or injection-related barriers.

Imaging and multidisciplinary care improve case finding. Ultrasound, magnetic resonance angiography and positron emission tomography help identify cranial and large-vessel disease. Faster diagnostic pathways increase the proportion of patients who enter specialist care and receive reimbursed maintenance medicine rather than episodic steroid treatment alone.

Market Restraints

Safety screening limits broad use of advanced therapies. Biologics and JAK inhibitors require attention to serious infection risk, laboratory abnormalities and patient-specific contraindications. JAK inhibitor labels also contain prominent warnings covering major cardiovascular events, malignancy and thrombosis. These considerations make treatment selection more complex in an older population with common comorbidities.

Diagnosis can be delayed or uncertain. GCA symptoms overlap with migraine, infection, polymyalgia rheumatica and other vascular disorders. Biopsy access and imaging expertise vary by health system. Empirical steroid use may begin before diagnostic confirmation, while atypical large-vessel disease can remain unrecognized.

Access remains uneven. Prior authorization, specialty-pharmacy requirements, biologic acquisition costs and limited rheumatology capacity restrict use in several markets. Biosimilars can ease budget pressure, but substitution rules, tender structures and clinician familiarity differ by country.

Market Opportunities

The strongest opportunities lie in safer oral medicines, less frequent dosing, biomarkers that predict relapse, therapies for refractory large-vessel disease and evidence supporting treatment discontinuation strategies. Real-world comparative studies can also clarify which patients benefit most from IL-6 inhibition, JAK inhibition or conventional immunosuppression. Manufacturers that pair clinical evidence with diagnostic education, adherence support and payer-ready steroid-toxicity models can improve both access and persistence.

Segmentation Analysis

By Drug Type

Biologics led the market with 43.5% of 2025 revenue, or USD 482.3 million. Tocilizumab remains the central biologic in GCA because it has an established regulatory indication and long-term physician familiarity. Branded and biosimilar products compete within this segment, expanding supply while placing pressure on net prices. Continued use is supported by steroid-sparing efficacy, but laboratory monitoring, infection precautions and injectable administration shape patient selection.

Corticosteroids represented 25%, equal to USD 277.2 million. Their revenue share is lower than their patient-use share because generic oral products are inexpensive. Prednisone and prednisolone remain the foundation of initial treatment, while intravenous methylprednisolone may be used when visual ischemia is threatened. Volume will remain high through 2035, although revenue growth will trail advanced therapies as clinicians seek shorter exposure.

Immune-suppressing agents held 18%, or USD 199.6 million. This category includes conventional medicines such as methotrexate and targeted oral agents used to reduce relapse. Upadacitinib is expected to raise the category’s value share through 2035 because it combines oral administration with GCA-specific clinical evidence. Conventional agents retain a place where biologic access is limited or clinicians seek lower-cost steroid-sparing options.

Anticoagulants and antiplatelet-supportive therapies accounted for 7.5%, or USD 83.2 million. These medicines are not disease-modifying GCA treatments and are used selectively according to ischemic and cardiovascular risk. Other therapies generated the remaining 6%, or USD 66.5 million, including supportive products used to manage treatment-related bone, gastric and metabolic risks.

By Route of Administration

Subcutaneous administration generated 46% of market revenue in 2025, equal to USD 510.0 million. The segment benefits from weekly tocilizumab regimens, home administration and the arrival of biosimilar prefilled syringes and autoinjector formats. Its lead should persist, though oral targeted therapy will narrow the gap.

Oral medicines accounted for 34%, or USD 377.0 million. The route covers high-volume glucocorticoids, conventional immunosuppressants and upadacitinib. Oral treatment reduces injection burden and supports routine dispensing, but adherence, drug interactions and class-specific safety monitoring remain important.

Intravenous products held 17%, or USD 188.5 million. Revenue is linked to acute glucocorticoid treatment, infusion-based immunomodulation and patients requiring supervised administration. Other routes represented 3%, or USD 33.3 million, and serve limited supportive-care needs.

By Distribution Channel

Hospital pharmacies led with 49% of 2025 revenue, or USD 543.3 million. Hospitals and specialist centers manage urgent diagnosis, threatened vision, infusion services and the initiation of high-cost therapy. Their share is reinforced by institutional procurement and payer authorization processes.

Retail pharmacies generated 38%, or USD 421.3 million. They dispense oral corticosteroids, methotrexate, supportive medicines and, where permitted, repeat prescriptions for targeted oral treatment. The channel benefits as stable patients move from induction to community-based maintenance.

Online and mail-order pharmacies accounted for 13%, or USD 144.1 million. Growth is being supported by specialty-pharmacy networks, cold-chain delivery and home distribution of recurring prescriptions. Uptake depends on national e-pharmacy regulation and reliable patient support for injectable therapies.

Regional and Country-Level Analysis

North America

North America led the global market with 42% of 2025 revenue, equal to USD 465.7 million. The region combines strong rheumatology access, broad use of specialty medicines, established biologic reimbursement and rapid uptake of newly approved targeted treatment. The United States contributed 36% of global revenue, or USD 399.1 million. Its position reflects high treatment prices, a large older population and early commercial access to both tocilizumab products and upadacitinib. Canada represented 4%, or USD 44.3 million, with provincial formularies and health-technology assessments influencing the speed and breadth of advanced-therapy access. Mexico and the remaining North American markets supplied the balance, with greater reliance on corticosteroids and conventional immunosuppression.

Europe

Europe held 31% of global revenue in 2025, equal to USD 343.7 million. High GCA recognition, ageing demographics and organized specialist pathways support treatment demand. Biosimilar competition and country-level tenders moderate expenditure per patient while widening biologic access. Germany accounted for 6.5% of global revenue, or USD 72.1 million, supported by specialist prescribing and broad insurance coverage. The United Kingdom held 5.5%, or USD 61.0 million, where National Health Service guidance and regional pathways influence sequencing. France generated 5%, or USD 55.4 million, aided by specialist centers and national reimbursement. Italy, Spain, the Nordic countries and the rest of Europe together formed the majority of regional demand. Northern European countries have a notable epidemiologic burden, while price controls limit revenue relative to treated volume.

Asia-Pacific

Asia-Pacific represented 20% of global sales, or USD 221.7 million, and is positioned for the fastest expansion through 2035. Japan accounted for 5% of global revenue, or USD 55.4 million, reflecting biologic experience and an ageing population. China held 4.5%, or USD 49.9 million; its growth is linked to improving diagnosis, hospital access and inclusion of advanced medicines in reimbursement channels. Australia and South Korea contribute established specialty-care demand, while India and Southeast Asia remain weighted toward generic corticosteroids and conventional immunosuppression. The main regional constraint is unequal access to rheumatology, vascular imaging and reimbursed biologics outside major cities.

Latin America

Latin America accounted for 4% of global revenue in 2025, or USD 44.3 million. Brazil is the largest national market, followed by Mexico and Argentina. Private insurance and tertiary hospitals support advanced treatment, but public-system access can be constrained by procurement cycles, specialist shortages and out-of-pocket costs. Biosimilar availability offers a practical route to wider IL-6 inhibitor use.

Middle East and Africa

The Middle East and Africa generated 3%, or USD 33.3 million. Gulf states, Israel, South Africa and major urban referral centers account for most advanced-therapy revenue. Diagnosis and sustained access remain limited across lower-resource markets. Investment in rheumatology training, vascular imaging and reliable specialty-drug distribution will determine long-term growth.

Competitive Landscape

Competition centers on reducing relapse, sustaining steroid-free remission, improving convenience and controlling total treatment cost. Roche and Genentech established the biologic standard with Actemra, while Fresenius Kabi and Celltrion entered with tocilizumab biosimilars. AbbVie differentiates RINVOQ through oral administration and a distinct JAK1-focused mechanism. Pricing, formulary placement, autoinjector usability, safety monitoring and long-term comparative evidence will determine share movement through 2035.

Pipeline risk remains material. GCA trials face fluctuating symptoms, steroid-taper effects and demanding sustained-remission endpoints. Failed late-stage programs demonstrate that efficacy in related inflammatory diseases does not guarantee success in GCA. The competitive advantage will favor companies that generate durable remission data, define safe maintenance duration and show measurable reductions in glucocorticoid toxicity.

AbbVie Inc.

AbbVie markets RINVOQ (upadacitinib), an oral selective and reversible JAK inhibitor for adults with GCA. The product is supplied as an extended-release tablet and offers an alternative to injectable steroid-sparing therapy. Its GCA program is supported by SELECT-GCA, a randomized Phase III study that evaluated upadacitinib with a 26-week glucocorticoid taper against placebo with longer tapering. Two-year continuation data reinforce the product’s maintenance proposition, although prescribing must account for the boxed safety warnings and individual infection, cardiovascular, malignancy and thrombosis risks. AbbVie’s established immunology sales network, payer contracting capabilities and experience across multiple RINVOQ indications support market penetration.

F. Hoffmann-La Roche Ltd / Genentech, Inc.

Roche’s Genentech markets Actemra/RoActemra (tocilizumab), an interleukin-6 receptor inhibitor and the first FDA-approved therapy for adult GCA. The GCA indication is associated with subcutaneous administration alongside a glucocorticoid taper, followed by use according to clinical circumstances. The pivotal GiACTA trial established higher sustained-remission rates than placebo-based steroid tapers and shaped the modern steroid-sparing treatment model. Roche’s strengths include long-term safety experience, global regulatory coverage and deep biologics manufacturing capability. Competitive pressure is increasing as biosimilars enter major markets, making brand trust, device support and continuity of supply central to Actemra’s position.

Fresenius Kabi AG

Fresenius Kabi participates through TYENNE (tocilizumab-aazg in the United States), a biosimilar to Actemra/RoActemra. The portfolio includes subcutaneous and intravenous presentations across approved inflammatory indications; GCA-specific use follows the applicable country label. The company’s prefilled syringe and autoinjector formats are relevant to long-term home administration. Fresenius Kabi combines biologics development with hospital and infusion-channel relationships, enabling it to compete on supply reliability, contracting and patient usability. TYENNE can widen access where payers favor biosimilars, but tender pricing and local interchangeability rules will shape adoption.

Celltrion, Inc.

Celltrion markets AVTOZMA (tocilizumab-anoh), a biosimilar developed for inflammatory diseases that include adult GCA under the U.S. label. Its intravenous and subcutaneous presentations give health systems flexibility across supervised and home-based care. The U.S. commercial availability of the subcutaneous formulation in March 2026 expanded competition in self-administered IL-6 inhibition. Celltrion’s vertically integrated biosimilar capabilities and global commercialization partnerships support price competition and supply expansion. Product education, contracting and confidence in switching from the reference medicine are the main levers for GCA uptake.

Recent Developments

• August 29, 2026: A nationwide French cohort analysis published online compared cardiovascular outcomes among 1,997 patients with GCA treated with tocilizumab or methotrexate. Two-year major adverse cardiovascular event incidence was 6.4% with tocilizumab and 10.7% with methotrexate; the adjusted hazard ratio was 0.60. As an observational analysis, the result supports further comparative research but does not establish causation.
• July 28, 2026: Two-year SELECT-GCA extension results were published online. Among responders re-randomized at week 52, disease flare occurred in 7.4% of patients who continued upadacitinib 15 mg and 59.5% of those switched to placebo. Glucocorticoid-free remission was maintained by 71.7% and 31.4%, respectively, while median glucocorticoid exposure was 0 mg versus 1,048 mg from weeks 52 to 104.
• April–September 2026: No additional GCA-specific drug approval or pivotal Phase III company announcement was identified on the official websites of the profiled manufacturers within the defined six-month window. Earlier approvals and product launches are treated as competitive background rather than recent developments.

Strategic Takeaways

• Prioritize steroid-sparing value: the strongest evidence packages will quantify sustained remission, cumulative glucocorticoid reduction and avoided toxicity.
• Prepare for route competition: oral targeted treatment challenges the convenience advantage historically held by self-injected biologics.
• Differentiate beyond molecule similarity: biosimilar success depends on device usability, contracting, supply continuity and switching support.
• Build country-specific access plans: U.S. specialty-pharmacy dynamics differ materially from European tenders and Asia-Pacific reimbursement pathways.
• Invest in long-term evidence: relapse after treatment withdrawal and optimal maintenance duration remain decisive clinical questions.
• Link therapy to faster diagnosis: partnerships around ultrasound training and referral pathways can expand the treated population without changing disease prevalence.
• Maintain disciplined safety communication: older patients often have cardiovascular, infection and malignancy risks that directly influence treatment choice.

Why Purchase the Report?

• To visualize the global giant cell arteritis drugs market segmentation based on drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of giant cell arteritis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global giant cell arteritis drugs market report would provide approximately 62 tables, 55 figures, and 283 pages.

Target Audience

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies